AN2 THERAPEUTICS INC's ticker is and the CUSIP is 037326105. A total of 38 filers reported holding AN2 THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,517,552 | +213.6% | 1,089,400 | +65.8% | 0.70% | +261.5% |
Q2 2023 | $5,586,200 | -21.7% | 657,200 | -9.1% | 0.20% | -17.7% |
Q1 2023 | $7,137,984 | +0.7% | 723,200 | -2.7% | 0.24% | +53.9% |
Q4 2022 | $7,086,508 | -45.1% | 743,600 | +0.1% | 0.15% | -41.2% |
Q3 2022 | $12,907,000 | +141.9% | 742,630 | +7.9% | 0.26% | +114.8% |
Q2 2022 | $5,335,000 | -48.6% | 688,330 | 0.0% | 0.12% | -43.5% |
Q1 2022 | $10,373,000 | – | 688,330 | – | 0.22% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Monashee Investment Management LLC | 233,330 | $4,055,000 | 1.50% |
RA Capital Management | 3,773,517 | $65,584,000 | 1.40% |
BVF INC/IL | 1,616,665 | $28,098,000 | 1.16% |
Avidity Partners Management LP | 742,630 | $12,907,000 | 0.26% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 716,538 | $12,453,000 | 0.25% |
Alyeska Investment Group, L.P. | 105,718 | $1,837,000 | 0.02% |
Woodline Partners LP | 76,145 | $1,323,000 | 0.02% |
Citadel Advisors | 1,336,983 | $23,237,000 | 0.01% |
ETF MANAGERS GROUP, LLC | 5,726 | $100,000 | 0.00% |
CITIGROUP INC | 134,545 | $2,338,000 | 0.00% |